<DOC>
	<DOCNO>NCT02547935</DOCNO>
	<brief_summary>The purpose clinical research study determine whether dapagliflozin alone combination saxagliptin decrease albuminuria improve glycemic control patient Type 2 diabetes , albuminuria renal impairment ( CKD ) . The study plan randomize total 450 patient ( 150 patient per treatment arm ) .</brief_summary>
	<brief_title>A Study Evaluate Effect Dapagliflozin With Without Saxagliptin Albuminuria , Investigate Effect Dapagliflozin Saxagliptin HbA1c Patients With Type 2 Diabetes CKD</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Female male age ≥18 year History type 2 diabetes mellitus 12 month HbA1c≥7.0 % ≤11.0 % Stable antidiabetic treatment last 12 week randomization eGFR 2575 mL/minute/1.73m2 , inclusive Micro macroalbuminuria ( UACR 30 3500 mg/g ) Treatment ACE inhibitor ARB least 3 month prior screen Body mass index 20 45 kg/m2 Any follow CV/Vascular Diseases within 3 month prior sign consent Visit 1 : Myocardial infarction cardiac surgery revascularization ( CABG/PTCA ) unstable angina unstable HF New York Heart Association ( NYHA ) Class IIIIV transient ischemic attack ( TIA ) significant cerebrovascular disease unstable previously undiagnosed arrhythmia Significant hepatic disease , include , limited , chronic active hepatitis and/or severe hepatic insufficiency Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) &gt; 3X ULN Total Bilirubin ( TB ) &gt; 2 mg/dL ( 34.2 μmol/L ) History acute kidney injury require renal replacement therapy ( dialysis ultrafiltration ) biopsy image verify intercurrent kidney disease diabetic nephropathy diabetic nephropathy nephrosclerosis Ongoing treatment SGLT2 inhibitor , GLP1 agonist DPP4 inhibitor Any condition , judgment Investigator , may render patient unable complete study may pose significant risk patient patient suspect confirmed poor protocol medication compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>